A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes

Following the clinical success achieved with the first generation of adoptive cell therapy (ACT) utilizing in vitro expanded tumor-infiltrating lymphocytes (TILs), the second and third generations of TIL ACT are evolving toward the use of genetically modified TIL. TIL therapy generally involves the...

Descripción completa

Detalles Bibliográficos
Autores principales: Forget, Marie-Andrée, Tavera, René J., Haymaker, Cara, Ramachandran, Renjith, Malu, Shuti, Zhang, Minying, Wardell, Seth, Fulbright, Orenthial J., Toth, Chistopher Leroy, Gonzalez, Audrey M., Thorsen, Shawne T., Flores, Esteban, Wahl, Arely, Peng, Weiyi, Amaria, Rodabe N., Hwu, Patrick, Bernatchez, Chantale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539190/
https://www.ncbi.nlm.nih.gov/pubmed/28824634
http://dx.doi.org/10.3389/fimmu.2017.00908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539190/
https://www.ncbi.nlm.nih.gov/pubmed/28824634
http://dx.doi.org/10.3389/fimmu.2017.00908

Ejemplares similares